Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of Luminex Co. (NASDAQ:LMNX) by 46.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 49,078 shares of the medical instruments supplier’s stock after selling 42,372 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.11% of Luminex worth $1,134,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Texas Permanent School Fund grew its stake in shares of Luminex by 3.9% during the 4th quarter. Texas Permanent School Fund now owns 27,131 shares of the medical instruments supplier’s stock worth $627,000 after acquiring an additional 1,028 shares during the period. Teachers Advisors LLC grew its stake in shares of Luminex by 0.6% during the 3rd quarter. Teachers Advisors LLC now owns 294,425 shares of the medical instruments supplier’s stock worth $8,924,000 after acquiring an additional 1,642 shares during the period. NumerixS Investment Technologies Inc bought a new position in shares of Luminex during the 4th quarter worth $39,000. TIAA CREF Investment Management LLC grew its stake in shares of Luminex by 0.7% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 264,642 shares of the medical instruments supplier’s stock worth $8,021,000 after acquiring an additional 1,793 shares during the period. Finally, Stone Ridge Asset Management LLC grew its stake in shares of Luminex by 9.1% during the 3rd quarter. Stone Ridge Asset Management LLC now owns 24,385 shares of the medical instruments supplier’s stock worth $739,000 after acquiring an additional 2,027 shares during the period. Institutional investors own 84.56% of the company’s stock.
Shares of NASDAQ LMNX opened at $23.98 on Friday. Luminex Co. has a 52 week low of $19.20 and a 52 week high of $35.37. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of 49.96, a P/E/G ratio of 5.58 and a beta of 0.79.
Luminex (NASDAQ:LMNX) last issued its earnings results on Monday, February 4th. The medical instruments supplier reported $0.04 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.08). Luminex had a return on equity of 4.61% and a net margin of 5.81%. The company had revenue of $81.10 million during the quarter, compared to the consensus estimate of $80.76 million. During the same quarter in the prior year, the business earned $0.20 EPS. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. On average, equities analysts expect that Luminex Co. will post 0.29 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Thursday, March 21st will be paid a $0.06 dividend. The ex-dividend date of this dividend is Wednesday, March 20th. This represents a $0.24 annualized dividend and a yield of 1.00%. Luminex’s dividend payout ratio is currently 50.00%.
Several research firms have recently weighed in on LMNX. TheStreet downgraded Luminex from a “b-” rating to a “c+” rating in a research note on Friday, December 14th. Zacks Investment Research downgraded Luminex from a “hold” rating to a “sell” rating in a research note on Friday, January 18th. BidaskClub downgraded Luminex from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. Finally, ValuEngine downgraded Luminex from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $28.40.
WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2019/03/17/connor-clark-lunn-investment-management-ltd-cuts-stake-in-luminex-co-lmnx.html.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
See Also: What is a Swap?
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.